Cookson Peirce & CO Inc Genmab A/S Transaction History

Cookson Peirce & CO Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 11, 2021	SELL	$30.92 - $44.4 $245,504 - $352,536	-7,940 Closed	0 $0
Q4 2020 Feb 10, 2021	SELL	$33.66 - $40.76 $939,753 - $1.14 Million	-27,919 Reduced 77.86%	7,940 $322,000
Q3 2020 Nov 04, 2020	BUY	$33.07 - $38.68 $298,919 - $349,628	9,039 Added 33.7%	35,859 $1.31 Million
Q2 2020 Aug 07, 2020	SELL	$20.05 - $33.89 $167,678 - $283,422	-8,363 Reduced 23.77%	26,820 $908,000
Q1 2020 May 04, 2020	BUY	$17.15 - $25.22 $58,618 - $86,201	3,418 Added 10.76%	35,183 $745,000
Q4 2019 Jan 27, 2020	BUY	$18.88 - $24.14 $599,723 - $766,807	31,765 New	31,765 $709,000

246

61.3M

159K

38K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $14.5B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Cookson Peirce & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Cookson Peirce & CO Inc with notifications on news.